Registro:

Referencias:

• Luke, M.C., Coffey, D.S., The Male Sex Accessory Tissues (1994) The Physiology of Reproduction, pp. 1435-1487. , Knobil E, Neill J. (eds). New York: Raven Press Ltd
• Rohr, H.P., Bartsch, G., Human benign prostatic hyperplasia. A stromal disease? (1980) Urology, 16 (6), pp. 625-633
• Getzenberg, R.H., Pienta, K.J., Coffey, D.S., The tissue matrix: Cell dynamics and hormone action (1990) Endocr Rev, 11 (3), pp. 399-416
• Bartsch, G., Brungger, A., Schweikert, U., Hinter, H., Stanzlu, J., Marth, C., The importance of stromal tissue in benign prostatic hyperplasia: Morphological, immunofluorescence and endocrinological investigations (1984) New Approaches to the Study of Benign Prostatic Hyperplasia, pp. 179-192. , Kimball FA, Buhl AE and Carter DB (eds) New York: Alan R. Liss
• Cunha, G., Wang, Y., Hayward, S., Risbridger, G., Estrogenic effects on prostatic differentiation and carcinogenesis (2001) Reprod Fertil Dev, 13 (4), pp. 285-296
• Nevalainen, M.T., Valve, E., Ingleton, P., Nurmi, M., Martikainen, P., Harkonen, P., Prolactin and prolactin receptors are expressed and functioning in human prostate (1997) J Clin Invest, 99 (4), pp. 618-627
• Barañao, J.L.S., Calvo, J.C., Luthy, I.A., Gonzalez, S.I., Charreau, E.H., Calandra, R.S., Prolactin effects on prepubertal male rat (1983) Recent Advances in Male Reproduction: Molecular Bases and Clinical Implications, 7, pp. 305-312. , R D'Agata, MB Lipsett, P Polosa, MJ van der Molen (editores). New York: Raven Press
• Costello, L.C., Franklin, R.B., Effects of prolactin on the prostate (1994) Prostate, 24 (3), pp. 162-166
• Reiter, E., Hennuy, B., Bruyninx, M., Cornet, A., Klung, M., McNamara, M., Effects of pituitary hormones on the prostate (1999) Prostate, 38 (2), pp. 159-165
• Hammond, G., Kontturi, M., Manttala, P., Puukka, M., Vihko, R., Serum FSH, LH and prolactin in normal males and patients with prostatic diseases (1977) Clin Endocrinol, 7 (2), pp. 129-135. , Oxf
• Price, D., Comparative aspects of development and structure in the prostate (1963) Natl Cancer Ins Monogr, 12, pp. 1-27
• Nevalainen, M.T., Valve, E.M., Makela, S.I., Blauer, M., Tuohimaa, P.J., Harkonen, P.L., Estrogen and prolactin regulation of rat dorsal and lateral prostate in organ culture (1991) Endocrinology, 129 (2), pp. 612-622
• Nevalainen, M.T., Valve, E., Ahonen, T., Yagi, A., Paranko, J., Harkonen, P., Androgen-dependent expression of prolactin in rat prostate epithelium in vivo and in organ culture (1997) FASEB J, 11 (14), pp. 1297-1307
• Barañao, J.L.S., Tesone, M., Oliveira-Filho, R.M., Chiauzzi, V.A., Calvo, J.C., Charreau, E.H., Effects of prolactin on prostate androgen receptors in male rats (1982) J Androl, 3, pp. 281-288
• Prins, G., Prolactin influence of cytosol and nuclear androgen receptors in the ventral, dorsal and lateral lobes in the rat prostate (1987) Endocrinology, 120 (4), pp. 1457-1464
• Wennbo, H., Kindblom, J., Isaksson, O., Tornell, J., Transgenic mice overexpression of the prolactin gene development dramatic enlargement of the prostate gland (1997) Endocrinology, 138 (10), pp. 4410-4415
• Blanchere, M., Mestayer, C., Saunier, E., Broshuis, M., Mowszowicz, I., Transforming growth factor beta in the human prostate: Its role in stromal-epithelial interactions in non-cancerous cell culture (2001) Prostate, 46 (4), pp. 311-318
• Niu, Y., Xu, Y., Zhang, J., Bai, J., Yang, H., Ma, T., Proliferation and differentiation of prostatic stromal cells (2001) Br J Urol, 87 (4), pp. 386-393
• Carruba, G., Webber, M., Quader, S., Amoroso, M., Cocciadiferro, L., Saladino, F., Regulation of cell-to-cell communication in non-tumorigenic and malignant human prostate epithelial cells (2002) Prostate, 50 (2), pp. 73-82
• Cussenot, O., Teillac, C., Le Duc, A., Kettels, F., Calvo, F., Culture de célules normales et tumorales de prostate humane (1989) Ann Urol, 23, pp. 533-537
• Orniz, D.M., Xu, J., Colvin, J.S., McEween, D.G., Mac Arthur, C.A., Coulier, F., Receptor specificity of the fibroblast growth factor family (1996) J Biol Chem, 271 (25), pp. 15292-15297
• Deshmukh, N., Scotson, J., Dodson, A., Smith, P., Ke, Y., Foster, C., Differential expression of acidic and basic fibroblast growth factors in benign prostatic hyperplasia identified by immunohistochemistry (1997) Br J Urol, 80 (6), pp. 869-874
• Piek, E., Heldin, C.H., Ten Dijke, P., Specificity, diversity and regulation in TGF-β superfamily signaling (1999) FASEB J, 13 (15), pp. 2105-2124
• Oklu, R., Hesketh, R., The latent transforming growth factor β binding protein (LTBP) family (2000) Biochem J, 352 (3 PART), pp. 601-610
• Marcelli, M., Cunningham, G.R., Hormonal signaling in prostatic hyperplasia and neoplasia (1999) J Clin Endoc Metab, 84 (10), pp. 3463-3468
• Tunn, S., Nass, R., Ekkernkamp, A., Schulze, H., Krieg, M., Evaluation of average life span of epithelial and stromal cells of human prostate by superoxide dismutase activity (1989) Prostate, 15 (3), pp. 263-271
• Shapiro, E., Becich, M.J., Hartanto, V., Lepor, H., The relative proportion of stromal and epithelial hyperplasia is related to the development of symptomatic benign prostate hyperplasia (1992) J Urol, 147 (5), pp. 1293-1297
• Ball, E.M.A., Risbridger, G.P., New perspectives on growth factor-steroid interaction in the prostate (2003) Cyt Growth Fact Rev, 14 (1), pp. 5-16
• Eaton, C.L., Aetiology and pathogenesis of benign prostatic hyperplasia (2003) Curr Opin Urol, 13, pp. 7-10
• Begun, F.P., Story, M.T., Hopp, K.A., Shapiro, E., Lawson, R.K., Regional concentration of basic fibroblast growth factor in normal and benign hyperplastic human prostate (1995) J Urol, 153 (3 PART 1), pp. 839-843
• Giri, D., Ropiquet, F., Ittmann, M., Alterations in expression of basic fibroblast growth factor (FGF)-2 and its receptor FGFR-1 in human prostate cancer (1999) Clin Cancer Res, 5 (5), pp. 1063-1071
• Ropiquet, F., Giri, D., Lamb, D.J., Ittmann, M., FGF7 and FGF2 are increased in benign prostatic hyperplasia and are associated with increased proliferation (1999) J Urol, 162 (2), pp. 595-599
• Ropiquet, F., Giri, D., Kwabi-Addo, B., Schmidt, K., Ittmann, M., FGF10 is expressed at low levels in the human prostate (2000) Prostate, 44 (4), pp. 334-338
• Thomson, A.A., Cunha, G.R., Prostatic growth and development are regulated by FGF10 (1999) Development, 126 (16), pp. 3693-3701
• Polnaszek, N., Kwabi-Addo, B., Wang, J., Ittmann, M., FGF17 is an autocrine prostatic epithelial growth factor and is upregulated in benign prostatic hyperplasia (2004) Prostate, 60 (1), pp. 18-24
• Cohen, P., Peehl, D.M., Rosenfeld, R.G., The IGF axis in the prostate (1994) Horm Met Res, 26 (2), pp. 81-84
• Bretland, A.J., Reid, S.V., Chapple, C.R., Eaton, C.L., Role of endogenous transforming growth factor beta (TGFbeta)1 in prostatic stromal cells (2001) Prostate, 48 (4), pp. 297-304
• Gonzalez Calvar, S.I., Salcedo, J.L., Martinez Mangini, M.A., Early detection of benign prostatic hyperplasia by assessment of TGFβ-2 plasmatic levels (2004) Biocell, 28 (1), p. 121
• Luo, J., Dunn, T., Ewing, C., Sauvageot, J., Chen, Y., Trent, J., Gene expression signature of benign prostatic hyperplasia revealed by cDNA microarray analysis (2002) Prostate, 51 (3), pp. 189-200
• Porena, M., Zucchi, A., Mearini, L., Mearini, E., Vivacqua, C., Testosterona e prostata (1999) IV International Congress on Therapy in Andrology. The Human Testis: Its Role in Reproduction and Sexuality, pp. 187-191. , Pisa-Italia; 14-16 octubre, Menchini Fabris GF (ed)
• Moalli, P.A., Klingensmith, W.L., Meyn, L.A., Zyczynski, H.M., Regulation of matrix metalloproteinase expression by oestrogen in fibroblast that are derived from the pelvic floor (2002) Am J Obstet Gynaecol, 187 (1), pp. 72-79
• Kang, H.Y., Lin, H.K., Hu, Y.C., Yen, S., Huang, K.E., Chang, C., From transforming growth factor-beta signaling to androgen action: Identification of Smad 3 as an androgen receptor coregulator in prostate cancer cells (2001) Proc Natl Acad Sci, 98 (6), pp. 3018-3023. , USA
• O'Callaghan, C.J., Williams, B., Regulation of human vascular smooth muscle extracelular matrix protein production by alpha and beta-adrenoreceptor stimulation (2002) J Hypertens, 20 (2), pp. 287-294
• Kyprianou, N., Chon, J., Benning, C.M., Effects of alpha-adrenoceptor antagonists on cell proliferation and apoptosis in the prostate: Therapeutic implications on prostatic disease (2000) Prostate, 9 (SUPPL.), pp. 42-49
• Giri, D., Ittmann, M., Interleukin-8 is a paracrine inducer of fibroblast growth factor 2, a stromal and epithelial growth factor in benign prostatic hyperplasia (2001) Am J Pathol, 159 (1), pp. 139-147
• Chicharro Molero, J.A., Burgos Rodríguez, R., Epidemiology of benign prostatic hyperplasia. Definition of the condition (1999) Rev Clin Española, 199 (2 SUPPL.), pp. 12-18
• Barry, M.J., Fowler Jr., F.J., O'Leary, M.P., Bruskewitz, R.C., Holtgrewe, H.L., Mebusk, W.K., The American Urological Association Sympton Index for benign prostatic hyperplasia (1992) J Urol, 148 (5), pp. 1549-1557. , The Measurement Committee of the American Urological Association
• Kirby, R.S., The natural history of benign prostatic hyperplasia: What have we learned in the last decade? (2000) Urology, 156 (1 SUPPL.), pp. 3-6
• Rodriguez Mora, V.L., Rodriguez Vallejo, J.M., García Alcázar, I., Gómez Acebo, A., Benign prostatic hyperplasia: Measurement of symptoms, IPSS and life quality assessment (1999) Rev Clin Esp, 199 (2 SUPPL.), pp. 30-35
• De La Rosette, J.J.M.C.H., Deric, K.E., Van Der Schoot, D.K.E., Debruyne, F.M.J., Recents developments in guidelines on benign prostatic hyperplasia (2002) Curr Op Urol, 12, pp. 3-6
• Salinas Sanchez, A.S., Hernandez Millán, I.R., Segura Martín, M., Lorenzo Romero, J.G., Lopez Torres Hidalgo, J., Virseda Rodriguez, J.A., Impact of prostatic symptoms in patients with prostatic benign hyperplasia (2000) Arch Esp Urol, 53 (3), pp. 212-224
• Gomez Acebo, A., Rodriguez Vallejo, J.M., Rodriguez Mora, V.I., García Alcázar, I., Quality of life and symptomatology in benign prostate hyperplasia in active Spanish population (2000) Med Clin, 114 (3 SUPPL.), pp. 81-89. , Barc
• Vela-Navarrete, R., Alfaro, V., Badiella, L.L., Fernandez, H.N., Age-stratified analysis of IPSS and QoL: Values in Spanish patients with symptoms potentially related to BPH (2000) Eur Urol, 38 (2), pp. 199-207
• O'Leary, M.P., LUTS, ED, QOL: Alphabet soup or real concerns to aging men? (2000) Urology, 565 (1 SUPPL.), pp. 7-11
• Kaplan, S., Garvin, D., Gilhooly, P., Koppel, M., Labasky, R., Milsten, R., Impact of baseline symptom severity on future risk of benign prostatic hyperplasia-related outcomes and long-term response to finasteride (2000) Urology, 156 (4), pp. 610-616
• Hammarsten, J., Hogstedt, B., Hyperinsulinaemia as a risk factor for developing benign prostatic hyperplasia (2001) Eur Urol, 39 (2), pp. 151-158
• Ooi, D.S., Innanen, V.T., Wang, D., Establishing reference intervals for DPC's free testosterone radioimmunoassay (1998) Clin Biochem, 31 (1), pp. 15-21
• Erfurth, E.M., Hagmar, L.E., Decreased serum testosterone and free triiodothyronine levels in healthy middle-aged men indicate an age effect at the pituitary level (1995) Eur J Endoc, 132 (6), pp. 663-667
• Vermeulen, A., Kaufman, J.M., Ageing of the hypothalamus-pituitary-testicular axis in men (1995) Hormone Res, 43 (1-3), pp. 25-28
• Teitz, N.W., Sheuy, D.F., Wekstein, D.R., Laboratory values in fit aging individuals-sexagenarians through centenarians (1992) Clin Chem, 38 (6), pp. 1167-1185
• Roberts, R.O., Jacobson, D.J., Rhodes, T., Klee, G.G., Leiber, M.M., Jacobsen, S.J., Serum sex hormones and measures of benign prostatic hyperplasia (2004) Prostate, , en prensa
• Pasquali, R., Casimini, F., Cantobelli, S., Melchionda, N., Morselli Labate, A.M., Fabbri, R., Effect of obesity and body fat distribution on sex hormones and insulin in men (1991) Metabolism, 40 (1), pp. 101-104
• Zamboni, M., Armellini, F., Turcato, E., De Pergola, G., Todesco, T., Bissoli, L., Relationship between visceral fat, steroid hormones and insulin sensitivity in premenopausal obese women (1994) J Int Med, 236 (5), pp. 521-527
• Haffner, S.M., Valdez, R.A., Mykkanen, L., Stern, M.P., Katz, M.S., Decreased testosterone and dehidroepiandrosterone sulfate concentrations are associated with increased insulin and glucose concentrations in nondiabetic men (1994) Metabolism, 43 (5), pp. 599-603
• Tsai, L., Johansson, C., Ponsette, A., Tagelman, R., Carlstron, K., Hemmingsson, P., Cortisol and androgen concentrations in females and male elite endurance athletes in relation to physical activity (1991) Eur J Appl Physiol Occup Physiol, 63, pp. 308-311
• Bartsch, G., Rittmaster, R.S., Klocker, H., Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia (2000) Eur Urol, 37 (4), pp. 367-380
• Vermeulen, A., De Sy, W., Androgens in patients with benign prostatic hyperplasia before and after prostatectomy (1976) J Clin Endoc Metab, 43 (6), pp. 1250-1254
• Barrack, E.R., Berry, S.J., DNA synthesis in the canine prostate: Effects of androgen and estrogen treatment (1987) Prostate, 10 (1), pp. 45-56
• Walsh, P.C., Wilson, J.D., The induction of prostatic hypertrophy in the dog with androstanediol (1976) J Clin Invest, 57 (4), pp. 1093-1097
• Winter, M.L., Liehr, J.G., Possible mechanism of induction of benign prostatic hyperplasia by estradiol and dihydrotestosterone in dogs (1996) Toxicol Appl Pharmacol, 136 (2), pp. 211-219
• Gray, A., Feldman, H., McKinlay, J., Longcope, C., Age, Disease, and changing sex hormone levels in middle-aged men: Results of the Massachusetts male aging study (1991) J Clin Endocrinol Metab, 73 (5), pp. 1016-1025
• Barone, D., Peroglio, F., Toso, E., Bruzzese, T., Binding of mepartricin to sex hormones, a key factor of its activity on benign prostatic hyperplasia (2001) Arzneimittelforschung, 51 (12), pp. 984-990
• Krieg, M., Nass, R., Tunn, S., Effect of aging on endogenous level of 5alpha-dihydrotestosterone, testosterone, estradiol and estrone in the epithelium and stroma of normal and hyperplastic human prostate (1993) J Clin Endoc Metab, 77 (2), pp. 375-381
• Labrie, F., Bélanger, A., Cusan, L., Candas, B., Physiological changes in dehydroepiandrosterone are not reflected by serum levels of active androgens and estrogens but of their metabolites: Intracrinology (1997) J Clin Endocrinol Metab, 82 (8), pp. 2403-2409
• Bélanger, A., Couture, J., Caron, S., Roy, R., Determination of non-conjugated and conjugates steroid levels in plasma and prostate after separation on C-18 columns (1990) Ann NY Acad Sci, 595, pp. 251-259
• Barbier, O., Lapointe, H., El Alfy, M., Hum, D.W., Belanger, A., Cellular localization of uridine diphosphoglucuronosyltransferase 2B enzymes in the human prostate by in situ hybridization and immunohistochemistry (2000) J Clin Endoc Metab, 85 (12), pp. 4819-4826
• Enriori, C.L., Enriori, P.J., La hiperplasia benigna de próstata como consecuencia de un defecto de la UDP-glucuroniltransferasa (1995) Acta Bioquím Clín Latinoam, 29 (2), pp. 167-172
• Wright, F., Poizat, R., Bongini, M., Bozzolan, F., Doukani, A., Mauvais-Jarvis, P., Decreased urinary 5alpha-androstane-3alpha,17beta-diol glucuronide excretion in patients with benign prostatic hyperplasia (1985) J Clin Endocrinol Metab, 60 (2), pp. 294-298
• Vermeulen, A., Clinical Reviews 24. Androgens in the aging male (1991) J Cin Endocr Metab, 73 (2), pp. 221-224
• Heller, J.E., Prostatic acid phosphatase: Its current clinical status (1987) J Urol, 137 (6), pp. 1091-1094
• Ellis, W.J., Brawer, M.K., Papel de los marcadores tumorales en el diagnóstico y tratamiento del cancer de próstata (1994) Enfermedades de la Próstata, pp. 337-358. , Lepor H y Lawson R (Eds), Madrid: Editorial Médica Panamericana, Capítulo 22
• Riegman, P.H.J., Vlietstra, R.J., Van Der Korput, J.A., Romijn, J.C., Trapman, J., Characterization of the prostate-specific antigen gene: A novel human kallikrein-like gene (1989) Biochem Biophys Res Commun, 159 (1), pp. 95-102
• Diamandis, E.P., Yu, H., New biological functions of prostate specific antigen? (1995) J Clin Endocrinol Metab, 80, pp. 1515-1517
• Enriori, P.J., Enriori, C.L., El antígeno prostático específico (PSA) y su actividad como una serin proteasa en ambos sexos (2000) Rev Arg Endoc Metab, 37 (1), pp. 9-17
• Sinha, A.A., Wilson, M.J., Gleason, D.F., Immunoelectron microscopic localization of prostatic-specific antigen in human prostate by the protein A-gold complex (1987) Cancer, 60 (6), pp. 1288-1293
• Fichtner, J., Graves, H.C., Thatcher, K., Yemoto, C., Shortliffe, M.L., Prostate specific antigen releases a kinin like substance on proteolysis of seminal vesicle fluid that stimulates smooth muscle contraction (1996) J Urol, 155 (2), pp. 738-742
• Stephenson, S.A., Verity, K., Ashworth, L.K., Clements, J.A., Localization of a new prostatic-specific antigen-related serine protease gene, KIK4, is evidence for an expended human kallikrein gene family cluster on chromosome; 19q13; 3-13; 4 (1999) J Biol Chem, 274 (33), pp. 23210-23214
• Magklara, A., Scorilas, A., Stephan, C., Cristiansen, G.O., Hauptmann, S., Jung, K., Decreased concentration of prostatic specific antigen (PSA) and human glandular kallikrein 2 (hk2) in malignant versus non-malignant prostatic tissue (2000) Urology, 56 (3), pp. 527-532
• Pollak, M., Beamer, W., Zhang, J.C., Insulin-like growth factors and prostate cancer (1998) Cancer Metastasis Rev, 17, pp. 383-390
• Morote, J., Encabo, G., López, M., De Torres, I.M., Prediction of prostate volume based on total and free serum prostate-specific antigen: Is it reliable? (2000) Eur Urol, 38 (1), pp. 91-95
• Roehrborn, C.G., McConnell, J., Bonilla, J., Rosemblatt, S., Hudson, P.B., Malek, G.H., Serum prostate specific antigen is a strong predictor of future prostate growth in men with benign prostatic hyperplasia. PROSCAR long-term efficacy and safety study (2000) J Urol, 163 (1), pp. 13-20
• Wright, E.J., Fang, J., Metter, J., Partin, A.W., Landis, P., Chan, D.W., Prostate specific antigen predicts the long-term risk of prostate enlargement: Results from the Baltimore Longitudinal study of aging (2002) J Urol, 167 (6), pp. 2484-2488
• Emberton, M., Andriole, G.L., De La Rosette, J., Djavan, B., Hoefner, K., Vela Navarrete, R., Benign Prostatic Hyperplasia: A Progressive disease of aging men (2003) Urology, 61 (2), pp. 267-273
• Jung, K., Elgeti, U., Lein, M., Vrux, B., Sinha, P., Rudolph, B., Ratio of free or complex prostate-specific antigen (PSA) to total PSA: Which ratio improves differentiation between benign prostatic hyperplasia and prostate cancer? (2000) Clin Chem, 46 (1), pp. 55-62
• Christensson, A., Bjork, T., Nilsson, O., Dahlen, U., Matikainen, M.T., Cockett, A.T., Serum prostate specific antigen complexed to alpha 1-antichymotrypsin as an indicator of prostate cancer (1993) J Urol, 150 (1), pp. 100-105
• Catalona, W.J., Smith, D.S., Ratliff, T.L., Dodds, K.M., Coplen, D.E., Yuan, J.J., Measurements of prostate specific antigen in serum as a screening test for prostate cancer (1991) N Engl J Med, 324 (17), pp. 1156-1161
• Emiliozzi, P., Longhi, S., Scarpone, P., Pansadoro, A., DePaula, F., Pansadoro, V., The value of a single biopsy with 12 transperineal cores for detecting prostate cancer in patients with elevated prostate specific antigen (2001) J Urol, 166 (3), pp. 845-850
• Catalona, W.J., Partin, A.W., Finlay, J.A., Chan, D.W., Rittenhouse, H.G., Wolfert, R.L., Use of percentage of free prostate specific antigen to identify men at a high risk of prostate cancer when PSA levels are 2.51 to 4 ng/ml and digital rectal examination is not suspicious for prostate cancer: An alternative model (1999) Urology, 54 (2), pp. 220-224
• Roehl, K.A., Antenor, J.A., Catalona, W.J., Robustness of free prostate specific antigen measurements to reduce unnecessary biopsies in the 2.6 to 4.0 ng/mL range (2002) J Urol, 168 (3), pp. 922-925
• Benson, M.C., Whang, I.S., Pantuck, A., Ring, K., Kaplan, S.A., Olsson, C.A., Prostate specific antigen density: A means to distinguish prostatic hypertrophy and prostate cancer (1992) J Urol, 147 (3 PART 2), pp. 815-816
• Carter, H.B., Pearson, J.D., Metter, E.J., Brant, L.J., Chan, D.W., Andres, R., Longitudinal evaluation of prostate specific antigen levels in men with and without prostate disease (1992) JAMA, 267 (16), pp. 2215-2220
• Ross, K.S., Carter, H.B., Pearson, J.D., Guess, H.A., Comparative efficiency of prostate-specific antigen screening strategies for prostate cancer detection (2000) JAMA, 284 (11), pp. 1399-1405
• Oesterling, J.E., Jacobsen, S.J., Cooner, W.H., The use of age specific reference ranges for serum prostate specific antigen in men 60 years old or older (1995) J Urol, 154 (3), pp. 1190-1195
• Allard, W.J., Zhou, Z., Yeung, K.K., Novel immunoassay for the measurement of complexed prostate-specific antigen in serum (1998) Clin Chem, 44 (6), pp. 1216-1223
• Filella, X., Alcover, J., Molina, R., Gimenez, N., Rodriguez, A., Jo, J., Clinical useful ness of free PSA fraction as an indicator of prostate cancer (1995) Int J Cancer, 63 (6), pp. 780-784
• Wymenga, L.F., Duisterwinkel, F.J., Groenier, K., Visser-van Brummen, P., Marrink, J., Mensink, H.J., Clinical implications of free-to-total immunoreactive prostate-specific antigen ratios (2000) Scand J Urol Nephrol, 34 (3), pp. 181-187
• Hofer, C., Sauerstein, P., Wolter, C., Scholz, M., Hartung, R., Breul, J., Value of free prostate-specific antigen (Hybritech Tandem-R) in symptomatic patients consulting the urologist (2000) Urol Int, 64 (1), pp. 18-23
• Chu, T.M., Lin, M.F., PSA and acid phosphatase in the diagnosis of prostate cancer (1998) J Clin Ligand Assay, 21 (1), pp. 24-34
• Oesterling, J.E., Prostate-specific antigen and diagnosing early malignancies of the prostate (1992) J Cell Biochem, (SUPL 16 H), pp. 31-43
• Bare, R., Hart, L., McCullough, D.L., Correlation of prostate-specific antigen and prostate-specific antigen density with outcome of prostate biopsy (1994) Urology, 43 (2), pp. 191-196
• Djavan, B., Zlotta, A., Kratzik, C., Remzi, M., Seitz, C., Schulman, C.C., PSA, PSA density, PSA density of transition zone, free/total PSA ratio, and PSA velocity for early detection of prostate cancer in men with serum PSA 2.5 to 4.0 ng/mL (1999) Urology, 54 (3), pp. 517-522
• Christensson, A., Laurell, C.B., Lilja, H., Enzymatic activity of prostate specific antigen and its reactions with extracellular serine proteinase inhibitors (1990) Eur J Biochem, 194 (3), pp. 755-763
• Charrier, J.P., Tournel, C., Michel, S., Dalbon, P., Jolivet, M., Two dimensional electrophoresis of prostate specific antigen in sera of men with prostate cancer or benign prostate hyperplasia (1999) Electrophoresis, 20 (4-5), pp. 1075-1081
• Jung, K., Brux, B., Lein, M., Rudolph, B., Kristiansen, G., Hauptmann, S., Molecular forms of prostate-specific antigen in malignant and benign prostatic tissue: Biochemical and diagnostic implications (2000) Clin Chem, 46 (1), pp. 47-54
• Mikolajczyk, S.D., Rittenhouse, H.G., Pro PSA: A more cancer specific form of prostate specific antigen for early detection of prostate cancer (2003) Keio J Med, 52 (2), pp. 86-91
• Mikolajczyk, S.D., Millar, L.S., Wang, T.J., Rittenhouse, H.G., Wolfert, R.L., Marks, L.S., "BPSA", a specific molecular form of free prostate-specific antigen, is found predominantly in the transition zone of patients with nodular benign hyperplasia (2000) Urology, 55 (1), pp. 41-45
• Linton, H.J., Marks, L.S., Millar, L.S., Knott, C.L., Rittenhouse, H.G., Mikolajczyk, S.D., Serum BPSA is elevated in men with benign prostate disease (2003) Clin Chem, 49 (2), pp. 253-259

Citas:

---------- APA ----------

---------- CHICAGO ----------

---------- MLA ----------

---------- VANCOUVER ----------